Back to the overview page

Brenda (BM) Luken PhD


Molecular biology and microbiology


Antibodies directed to ADAMTS13 in acquired thrombotic thrombocytopenic purpura
University of Utrecht
Promotor: Prof K Mertens
Co-promotores: J Voorberg PhD and R Fijnheer PhD

Research interests

I study structure-function relationships of proteins in the blood using various cutting-edge biochemical techniques, building on my extensive experience in VWF/ADAMTS13 research. In addition, I seek to translate these basic science results to clinical patient studies. My current research focusses on neutrophil extracellular traps (NETs) and their role in inflammation.

  • Protein biochemistry (ELISA, Western blot, etc)
  • Enzyme kinetic analysis
  • Circular dichroism
  • Differential scanning fluorometry
  • Biacore/SPR
  • Microfluidic perfusion assays (flow chamber)
  • Fluorescence microscopy
  • Immunoglobulin V-gene phage-display
  • Epitope mapping
  • Molecular biology and cloning techniques, site-directed mutagenesis
  • Protein structural analysis
  • Pulse chase labelling
  • Mammalian/insect cell tissue culture
  • Clinical patient studies
2014-present Postdoc Fellow, Dept of Immunopathology, Sanquin Research, Amsterdam
2011-2013 British Heart Foundation Basic Science Research Fellow, Centre for Haematology, Dept of Medicine, with Prof DA Lane. Imperial College London, United Kingdom
2007-2011 Post-doctoral Research Associate, Dept of Haematology with Prof DA Lane/Dr JTB Crawley. Imperial College London, United Kingdom
2005-2007 Post-doctoral Research Associate, Dept of Plasma Proteins, with Dr J Voorberg. Sanquin Research, Amsterdam
2001-2005 PhD at the Dept of Plasma ProteinsSanquin Research, Amsterdam, The Netherlands
1996-2000 MSc Biology, VU University, Amsterdam, The Netherlands
Sanquin publications
Other publications

Andersson HM, Siegerink B, Luken BM, Crawley JTB, Algra A, Lane DA, Rosendaal FR. High VWF, low ADAMTS13 and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young woman. Blood 2012; 119(6):1555-60.

Crawley JT, de Groot R; Xiang Y, Luken BM, Lane DA. Unravelling the scissile bond: how ADAMTS13 recognises and cleaves von Willebrand factor. Blood 2011; 118(12):3212-21.

Pos W; Luken BM, Sorvillo N, Hovinga JA,Voorberg J. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2011; 9(7):1285-91.

Luken BM, Winn LY, Emsley J, Lane DA, Crawley JT. The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood 2010; 115(23):4910-3.

Pos W, Crawley JT, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010; 115(8):1640-9.

Andersson HM, Arantes MJ, Crawley JT, Luken BM, Tran S, Dahlb├Ąck B, Lane DA, Rezende SM. Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood 2010; 115(23):4878-85.

Crawley JT; de Groot R; Luken BM. Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand. J Thromb Haemost 2009; 7(12):2085-7.

Luken BM. Extracellular control of VWF multimer size and thiol-disulfide exchange. J Thromb Haemost 2008; 6(7):1131-4.

Last edited on: 20 April 2016
Back to the overview page